CHMP besluttede, at fordelene ved Fabrazyme var større end risiciene til langsigtet enzymsubstitutionsbehandling af patienter med den bekræftede diagnose Fabry sygdom.
The CHMP decided that Fabrazyme’ s benefits are greater than its risks for long-term enzyme replacement therapy in patients with a confirmed diagnosis of Fabry disease.